Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07032662 · ClinicalTrials.gov registry record · Phase 2
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Immunovant Sciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
- 20
- Study locations
NCT07032662: Recruiting Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Immunovant Sciences.
NCT07032662 is a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Immunovant Sciences. The registered enrollment target is 162 participants, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07032662, a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Immunovant Sciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.
Primary Outcome
Relapse is defined as a worsening (increase) of ≥ 1 point on the adjusted inflammatory neuropathy cause and treatment (aINCAT) score at any time point relative to Period 1 Baseline.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG IMVT-1402
Study Locations (20)
Florida
- Site Number - 1603 - Maitland
- Site Number - 1606 - Miami
- Site Number - 1617 - Ormond Beach
- Site Number - 1620 - Port Charlotte
- Site Number - 1633 - Rockledge
California
- Site Number - 1618 - Carlsbad
- Site Number - 1619 - Orange
- Site Number - 1607 - Rancho Mirage
- Site Number -1608 - San Francisco
District of Columbia
- Site Number - 1630 - Washington D.C.
- Site Number - 1601 - Washington D.C.
Massachusetts
- Site Number - 1623 - Boston
- Site Number - 1625 - Worcester
Arizona
- Site Number - 1612 - Tucson
Colorado
- Site Number - 1626 - Parker
Connecticut
- Site Number - 1621 - New Haven
Kansas
- Site Number - 1602 - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2030-05 |
| Phase | Phase 2 |
What NCT07032662 shows while recruiting
NCT07032662 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (11% higher).
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07032662 names 20 study sites across 11 states, led by Florida, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT07032662 about?
NCT07032662 is a clinical study titled "IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". This is a Phase 2b study to evaluate the efficacy and safety of IMVT-1402 in adults with CIDP.
What is the current status of trial NCT07032662?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2025-03-18. Estimated completion is 2030-05.
What conditions does trial NCT07032662 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT07032662?
The interventions under investigation include: Placebo (DRUG), IMVT-1402 (DRUG).
Who is sponsoring clinical trial NCT07032662?
This trial is sponsored by Immunovant Sciences, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07032662 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07032662's enrollment target sits among peer trials
162 4th of 11 higher than 8 of 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Inflammatory Demyelinating Polyneuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
-
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
ACTIVE NOT RECRUITING · Phase 2
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI